Implementation of Functional Diagnostics using Patient-derived Tumor Organoids

Full Title: Implementation of Functional Diagnostics and High Throughput Drug Screening of Patient‐Derived Tumor Organoids Intro / 3D Cell Culture: From Promise to Reality: 00:00 – 6:52 Englander Institute for Precision Medicine Drug Discovery Platform: 6:53 – 10:30 EIPM tumor organoid platform pipeline: 10:31 – 17:28 EIPM organoid types: 17:29 – 18:59 High throughput drug screening Core: 19:00 -23:11 New tools: CRISPR screening: 23:12 – 25:47 Tumor microenvironment: 25:48 – 28:55 Human Cancer Model Initiative / summary: 28:56 – 31:45 Q&A session: 31:46 - 34:59 Precision medicine aims to match individual patients with the best treatment based on the patients’ tumors biologic and molecular characteristics. As part of the Englander Institute for Precision Medicine at Weill Cornell Medical College, the Tumor Organoid Platform is an active program focused on the development of Next Generation Cancer Models derived from metastatic and primary anatomic sites obtained through biopsies, surgical resections and rapid autopsy procedures. With this platform, they are able to extend their personalized medicine program to include high throughput drug screening, which can be validated through genomic sequencing and both in vivo and in vitro models.